GlobalData is a publicly owned company headquartered in the UK, founded in 2010 with approximately 2,380 employees. The company provides information services, functioning as a market research provider with a focus on market sizing research.
On February 21, 2026, GlobalData stated that India is prioritizing compliance resilience, supply diversification, and stronger U.S. energy linkages as part of a strategic energy security doctrine, given that oil accounts for approximately a quarter of India's primary energy consumption and import dependence stands at about 87 percent. Previously, a GlobalData analysis published on February 20 found that delays in monetizing approved drugs due to complex pricing and reimbursement processes rank among the pharmaceutical industry's top challenges, with a survey from the firm's State of the Biopharmaceutical Industry report indicating that industry professionals consider these processes among the top five factors affecting the sector. Earlier on February 20, a Q4 2025 survey by GlobalData revealed that 45 percent of consumers in Asia and Australasia are likely to purchase products based on AI recommendations or endorsements, noting that AI in the APAC retail sector is transitioning from analytics and pilots into workflows and daily operations, driven by factors such as dense urban stores and competitive quick-commerce ecosystems. On February 19, GlobalData highlighted significant opportunities for innovation and development in the pain market, citing a lack of diversity with non-steroidal anti-inflammatory drugs (NSAIDs) and opioids dominating, and noting that 98% of currently marketed pain drugs are generics.
Subscribe for full access to GlobalData's products in full detail
Subscribe for full access to GlobalData's revenue in full detail
Subscribe for full access to GlobalData's products in full detail 
